Factors predictive for MMR at 12 months (optimal response) including the type of BCR-ABL fusion transcript
| . | No MMR, N (%) . | MMR, N (%) . | OR . | 95% CI OR . | P . |
|---|---|---|---|---|---|
| Univariate* | |||||
| TKI type | |||||
| Imatinib 400† | 20 (23) | 24 (8) | |||
| Imatinib 800 | 33 (38) | 140 (45) | 3.54 | (1.75-7.15) | <.001 |
| Dasatinib | 22 (25) | 72 (23) | 2.73 | (1.27-5.84) | .010 |
| Nilotinib | 11 (13) | 77 (25) | 5.83 | (2.45-13.88) | <.001 |
| Transcript type | |||||
| e13a2‡ | 60 (70) | 101 (32) | |||
| e14a2 | 15 (17) | 151 (48) | 5.98 | (3.22-11.11) | <.001 |
| Both | 11 (13) | 61 (19) | 3.29 | (1.61-6.75) | .001 |
| Splenomegaly (≥10 cm) | |||||
| No | 76 (88) | 300 (96) | |||
| Yes | 10 (12) | 13 (4) | 0.33 | (0.14-0.78) | .012 |
| Platelets (>300 K/µL) | |||||
| No | 46 (53) | 123 (39) | |||
| Yes | 40 (46) | 190 (61) | 1.78 | (1.10-2.87) | .019 |
| Multivariate§ | |||||
| TKI type | |||||
| Imatinib 400† | 20 (23) | 24 (8) | |||
| Imatinib 800 | 33 (38) | 140 (45) | 4.83 | (2.20-10.62) | <.001 |
| Dasatinib | 22 (25) | 72 (23) | 3.39 | (1.45-7.89) | .005 |
| Nilotinib | 11 (13) | 77 (25) | 8.24 | (3.16-21.43) | <.001 |
| Transcript type | |||||
| e13a2‡ | 60 (70) | 101 (32) | |||
| e14a2 | 15 (17) | 151 (48) | 5.85 | (3.01-11.37) | <.001 |
| Both | 11 (13) | 61 (19) | 3.18 | (1.50-6.74) | .003 |
| . | No MMR, N (%) . | MMR, N (%) . | OR . | 95% CI OR . | P . |
|---|---|---|---|---|---|
| Univariate* | |||||
| TKI type | |||||
| Imatinib 400† | 20 (23) | 24 (8) | |||
| Imatinib 800 | 33 (38) | 140 (45) | 3.54 | (1.75-7.15) | <.001 |
| Dasatinib | 22 (25) | 72 (23) | 2.73 | (1.27-5.84) | .010 |
| Nilotinib | 11 (13) | 77 (25) | 5.83 | (2.45-13.88) | <.001 |
| Transcript type | |||||
| e13a2‡ | 60 (70) | 101 (32) | |||
| e14a2 | 15 (17) | 151 (48) | 5.98 | (3.22-11.11) | <.001 |
| Both | 11 (13) | 61 (19) | 3.29 | (1.61-6.75) | .001 |
| Splenomegaly (≥10 cm) | |||||
| No | 76 (88) | 300 (96) | |||
| Yes | 10 (12) | 13 (4) | 0.33 | (0.14-0.78) | .012 |
| Platelets (>300 K/µL) | |||||
| No | 46 (53) | 123 (39) | |||
| Yes | 40 (46) | 190 (61) | 1.78 | (1.10-2.87) | .019 |
| Multivariate§ | |||||
| TKI type | |||||
| Imatinib 400† | 20 (23) | 24 (8) | |||
| Imatinib 800 | 33 (38) | 140 (45) | 4.83 | (2.20-10.62) | <.001 |
| Dasatinib | 22 (25) | 72 (23) | 3.39 | (1.45-7.89) | .005 |
| Nilotinib | 11 (13) | 77 (25) | 8.24 | (3.16-21.43) | <.001 |
| Transcript type | |||||
| e13a2‡ | 60 (70) | 101 (32) | |||
| e14a2 | 15 (17) | 151 (48) | 5.85 | (3.01-11.37) | <.001 |
| Both | 11 (13) | 61 (19) | 3.18 | (1.50-6.74) | .003 |
White blood cell count, age, Sokal score, hemoglobin, peripheral blood blasts, and serum lactate dehydrogenase are not significant (P = not significant; data not shown).
Imatinib 400 is the reference for comparison with the other 3 TKI modalities.
e13a2 is the reference for comparison with e14a2 and both (coexpressed transcripts).
Platelet count and spleen size were not significant in multivariate analysis (data not shown).